By estrogenic stimulation, the receptor induces rapid but transient Erk1/2 activation to promote cell proliferation in ERα/ERβ-negative breast cancer cells as well as in endometrial, ovarian, and thyroid cancer cells [220,221,222]. This evidence concerns the gene MAPK3 and breast carcinoma.